GeneQuantum Healthcare's Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia

GeneQuantum Healthcare | May 16, 2022

GeneQuantum Healthcare's

GeneQuantum Healthcare Co., Ltd. a global innovative biotechnology company dedicated to the development of bioconjugate drugs, announced that two of the company's bioconjugate drug candidates have won the approval for clinical trials in Australia, further enhancing GeneQuantum's pipelines in the clinical stage. They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate both with global intellectual property rights.

"The core technologies that we have focused on since the founding of GeneQuantum, bring the company into the harvest period for exciting next generation bioconjugate drugs. The EC approval of GQ1005 and GQ1007 in Australia is an important milestone for the company. More than once, GeneQuantum's enzymatic site-specific conjugation platform and the stable linker technology have demonstrated the advantages through several IND enabled drug candidates.  GeneQuantum conjugation technologies are widely compatible to different molecular modalities with various Mechanism of Action. Committed to the core value of "breakthrough for humanity", GeneQuantum is dedicated to developing safe, effective, and affordable novel therapeutics for patients with cancer around the world."


Dr. Gang Qin, founder, Chairman and Chief Executive Officer


About GeneQuantum Healthcare Co., Ltd.

GeneQuantum Healthcare Co., Ltd. is a global biotechnology company dedicated to the development of innovative biotherapeutics. The company is focused on the development of next generation bioconjugate therapeutics to address the unmet medical needs of patients globally.  

This press release contains statements relating to GeneQuantum's future business, future events or developments, and related statements may constitute forward-looking statements. Statements are based on current expectations and assumptions that are subject to risks and uncertainties, which may cause actual results to differ materially. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, follow-up clinical data and analysis; factors that may cause any delay, transfer or change; regulatory authority decision whether and when to approve drug applications; factors that may lead actual results to seriously deviate from current expectations, etc. No forward-looking statement can be guaranteed. Except as required by applicable laws, GeneQuantum assumes no obligation to update or revise any forward-looking information or statements.


The future of Molecular Imaging is personal. Every step of the care you provide is an opportunity to make personalized decisions for your patients. One pathway focused on enabling intelligently efficient and precise, personalized care is Theranostics, the process of bringing together diagnostics and therapeutics.


The future of Molecular Imaging is personal. Every step of the care you provide is an opportunity to make personalized decisions for your patients. One pathway focused on enabling intelligently efficient and precise, personalized care is Theranostics, the process of bringing together diagnostics and therapeutics.

Related News


Whakarongorau Aotearoa Chooses Nice CXone for Contact Center Boost

Whakarongorau Aotearoa | March 13, 2023

NICE recently announced that Whakarongorau Aotearoa - New Zealand Telehealth Services has implemented its CXone cloud-native platform to modernize contact center operations as well as to provide seamless customer experiences in an effort to enhance the health of the general public in New Zealand. Whakarongorau Aotearoa, a social enterprise owned by ProCare and Pegasus Health, manages the government-funded National Telehealth Services Contract. The institution oversees national telehealth services via seven digital channels and various contact centers, ensuring public access to high-quality healthcare. Whakarongorau Aotearoa chose NICE and Converged Communication Network Applications (CCNA) to move its contact center environment to a mature, cloud-based, more scalable, and flexible solution to meet changing business needs. This will help it take advantage of strategic opportunities and meet transforming community needs digitally. Whakarongorau Aotearoa can meet New Zealand's National Telehealth Services' immediate needs and reporting needs with the help of NICE CXone. CXone's reporting capabilities provide granular insights for streamlined operations while supporting expansion to new channels and better serving the public. Mike Mulvaney, Director of Technology Services, Whakarongorau Aotearoa – New Zealand Telehealth Services, stated, "The health of the New Zealand public is of the utmost concern for Whakarongorau Aotearoa. NICE CXone enables us to rapidly respond to changing public health events, seamlessly scale the supporting workforce as needed without disruption to service users and will empower us to provide better service to reach even more New Zealanders." (Source – Business Wire) Darren Rushworth, President of NICE International, added, "CXone will provide Whakarongorau Aotearoa the ability to seamlessly move into its next phase of maturity and grow with the organization as it continues to evolve. CXone will allow them to support New Zealanders effectively and create exceptional customer experiences." (Source – Business Wire) About Whakarongorau Aotearoa Whakarongorau Aotearoa is a social enterprise jointly owned by ProCare and Pegasus Health. It oversees the management of New Zealand's Government-funded national telehealth services, which are available to the public free of charge around the clock via seven digital channels. The services provided by Whakarongorau Aotearoa include General Practice After Hours services and those covered under the National Telehealth Services Contract with the New Zealand government, which has been in effect since 2015.

Read More


DocGo Announces Strategic Mobile Health Agreement with Fresenius Medical Care

Businesswire | April 26, 2023

DocGo a leading provider of last-mile mobile health services, announced it has entered into a preferred provider agreement with Fresenius Medical Care (FMC) – the largest provider of kidney dialysis treatment in the United States. This preferred provider agreement includes remote patient monitoring, principal care management, chronic care management, and urgent care services. DocGo has been an FMC preferred medical transportation partner since 2019. The new multi-year agreement, expected to start on May 1, 2023, advances DocGo’s mission to provide high-quality, technology-driven care to patients, where it’s needed, when it’s needed, and ensure better experiences and outcomes. DocGo’s remote patient monitoring services will provide a solution for nephrologists to extend their reach and better manage patients’ conditions. Additionally, DocGo capabilities include after-hours support for urgent care needs, both treating on scene as well as ambulance transport when necessary. “Our relationship with Fresenius Medical Care positions DocGo to assist nephrologists with patient treatment, while growing and offering services that enable us to do what we do best: provide proactive care that mitigates a patient’s chance of hospitalization,” said Anthony Capone, CEO of DocGo. “By providing services such as remote patient monitoring, chronic care management and 24x7 mobile urgent care, our top-rated medical professionals can operate as an extension of nephrologists to help develop successful and accessible treatment plans that keep patients healthy longer.” DocGo's suite of services can help nephrologists better manage the condition of the 780,000-end stage renal disease patients and millions of chronic kidney disease patients that are currently estimated to reside in the U.S. by the Centers for Disease Control and Prevention. DocGo uses data from its remote patient monitoring program to continually assess a patient’s condition. If necessary, DocGo can also dispatch urgent care services and medical transportation to patients in need of immediate attention. By integrating into DocGo’s existing infrastructure and leveraging DocGo’s world-class AI technology, this DocGo/Fresenius Medical Care collaboration will help more patients manage their condition, stay healthier in their homes, and have beneficial health outcomes. About DocGo DocGo is a leading provider of last-mile mobile care services. DocGo is disrupting the traditional four-wall healthcare system by providing high quality, highly affordable care to patients where and when they need it. DocGo's innovative technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care.

Read More


WellSky® Unveils Patient Engagement Platform to Personalize Condition Management and Optimize Health Outcomes

Businesswire | April 10, 2023

WellSky, a leading health and community care technology company, today announced the launch of WellSky Patient, a transformative patient engagement platform aimed at identifying patient health risks, avoiding complications, and improving outcomes through stronger transparency and communication between patients, families, and clinical care teams. A patient’s willingness and ability to participate in their care plans, particularly between provider visits, can greatly influence whether they experience new health problems and subsequent use of costly, unplanned emergent care. With the WellSky Patient platform, patients stay connected to their care providers between visits through two-way communication, video-based telehealth, and guided condition management programs. At the same time, patient-generated data from health status submissions and remote monitoring creates a comprehensive view for clinicians to track a patient’s progression and identify needs for clinical intervention. “It is critical that our care team members have a complete picture of the patient’s condition and are given the insights necessary to engage most appropriately with the right resources at the right time,” said Dr. Bethany Snider, chief medical officer at Hosparus Health. “The capabilities WellSky is bringing to the table help give us the visibility we need to customize care to the individual, while also ensuring the patient’s family members and other caregivers are full participants in the care journey.” When patients are given convenient and practical tools to help them take an active role in their own care and well-being, satisfaction is higher, complications are fewer, and outcomes are better. By focusing on the home as the center of patient engagement, healthcare organizations can gain new insights into patient behaviors and conditions, enabling them to adjust the plan of care, control costs, and positively influence outcomes to the benefit of the person and the healthcare organization alike. “Patient engagement technology has historically focused on completing tasks related to a care episode, such as scheduling an appointment, completing an intake form, or viewing a lab result,” said Tim Ashe, chief clinical officer at WellSky. “That paradigm must shift toward the person, with a focus on how to best guide them through the care journey while surveying and managing their condition virtually. The innovation WellSky has developed to bring this strategy to life will be of great value to our clients, their care team members, and their patients.” By putting the person at the center of their own care, healthcare organizations can offer unique and differentiated care experiences while gaining unprecedented insights into when – and how – specific interventions can optimize outcomes for patients and ultimately ensure success in models of value-based care. About WellSky® WellSky is one of America’s largest and most innovative healthcare technology companies leading the movement for intelligent, coordinated care. Our proven software, analytics, and services power better outcomes and lower costs for stakeholders across the health and community care continuum. In today’s value-based care environment, WellSky helps providers, payers, health systems, and community organizations scale processes, improve collaboration for growth, harness the power of data analytics, and achieve better outcomes by further connecting clinical and social care. WellSky serves more than 20,000 client sites — including the largest hospital systems, blood banks, cell therapy labs, home health and hospice franchises, post-acute providers, government agencies, and human services organizations. Informed by more than 40 years of providing software and expertise, WellSky anticipates clients’ needs and innovates relentlessly to build healthy, thriving communities.

Read More